Mumbai, August 11, 2020: Pharma major Lupin Limited (Lupin) announced the launch of Zileuton Extended-Release Tablets, 600 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin’s Nagpur facility, India.
Zileuton Extended-Release Tablets, 600 mg, is the generic equivalent of Zyflo CR® Extended-Release Tablets, 600 mg, of Chiesi USA, Inc. and is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
Zileuton Extended-Release Tablets (RLD: Zyflo CR®) had an annual sales of approximately USD 40 million in the U.S. (IQVIA MAT June 2020).
Corporate Comm India (CCI Newswire)
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…